Skip to main content

Table 4 14-3-3η levels by therapy group at baseline and after 1 year of therapy

From: Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab

Group Sample size Pretreatment 14-3-3η 14-3-3η at 1 yr p Value
Whole cohort 149 0.70 (0.17–5.96) 0.37 (0.11–1.82) <0.0001
Adalimumab 49 0.62 (0.16–4.66) 0.38 (0.13–1.40) <0.0001
Methotrexate 23 0.67 (0.17–1.89) 0.33 (0.11–1.44) 0.0101
Tocilizumab 50 0.43 (0.15–8.40) 0.27 (0.10–2.58) 0.0007
Tofacitinib 27 1.30 (0.21–9.46) 1.26 (0.11–3.07) 0.013
  1. Median (interquartile range) 14-3-3η serum titers at baseline and at 1 yr are compared with the whole cohort and each therapy group. Corresponding Wilcoxon matched-pairs signed-rank test values were calculated